Screener
Intellia Therapeutics NTLA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
FAQ
- What is Intellia Therapeutics's cash & equivalents?
- Intellia Therapeutics (NTLA) reported cash & equivalents of $106.13M in Q2 2026.
- How has Intellia Therapeutics's cash & equivalents changed year-over-year?
- Intellia Therapeutics's cash & equivalents decreased by 32.0% year-over-year, from $156.17M to $106.13M.
- What is the long-term trend for Intellia Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Intellia Therapeutics's cash & equivalents has grown at a -0.6% compound annual growth rate (CAGR), from $160.02M to $155.46M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Intellia Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude